Opdivo-Yervoy (nivolumab-ipilimumab)

pCPA File Number: 21557

Negotiation Status:

Concluded with an LOI

Indication(s):

Unresectable malignant pleural mesothelioma (MPM) in adult patients who have not received prior systemic therapy for MPM (in combination with ipilimumab)

Sponsor/Manufacturer:

Bristol Myers Squibb Canada Inc.

CDA-AMC Project Number:

PC0229-000

pCPA Engagement Letter Issued:

2021-10-29

Negotiation Process Concluded:

2022-01-18